BACKGROUND: Studies assessing the efficacy of liposomal amphotericin B (LAB) in the treatment of patients with mucosal leishmaniasis (ML) are very scarce in the literature and an optimal dose regimen has not yet been defined. METHODS: We performed a retrospective and descriptive analysis from records of 16 patients with ML treated with LAB. The mean daily dose of LAB was 2.5 mg/kg/day. RESULTS: Healing of the lesion was observed in 14 (88%) of the 16 patients. The mean cumulative doses, excluding the two treatment failures, were 2265 mg and 33 mg/kg. CONCLUSION: Liposomal amphotericin B in the cumulative dose of 30 to 35 mg/kg was able to achieve 100% effectiveness.
BACKGROUND: Studies assessing the efficacy of liposomal amphotericin B (LAB) in the treatment of patients with mucosal leishmaniasis (ML) are very scarce in the literature and an optimal dose regimen has not yet been defined. METHODS: We performed a retrospective and descriptive analysis from records of 16 patients with ML treated with LAB. The mean daily dose of LAB was 2.5 mg/kg/day. RESULTS: Healing of the lesion was observed in 14 (88%) of the 16 patients. The mean cumulative doses, excluding the two treatment failures, were 2265 mg and 33 mg/kg. CONCLUSION: Liposomal amphotericin B in the cumulative dose of 30 to 35 mg/kg was able to achieve 100% effectiveness.
Authors: Antonio Carlos Nicodemo; Heitor Franco de Andrade; Pablo Muñoz Torres; Valdir Sabbaga Amato Journal: Am J Trop Med Hyg Date: 2019-08 Impact factor: 2.345
Authors: Felipe Francisco Tuon; Leticia Ramos Dantas; Regina Maia de Souza; Victoria Stadler Tasca Ribeiro; Valdir Sabbaga Amato Journal: Parasitol Res Date: 2022-09-16 Impact factor: 2.383
Authors: Gert-Jan Wijnant; Katrien Van Bocxlaer; Vanessa Yardley; Andy Harris; Mo Alavijeh; Rita Silva-Pedrosa; Sandra Antunes; Isabel Mauricio; Sudaxshina Murdan; Simon L Croft Journal: Int J Parasitol Drugs Drug Resist Date: 2018-04-12 Impact factor: 4.077